PRINCETON, N.J., Feb. 11, 2021 /PRNewswire/ -- Soligenix,
Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage
biopharmaceutical company focused on developing and commercializing
products to treat rare diseases where there is an unmet medical
need, announced today that its President and Chief Executive
Officer, Christopher J. Schaber,
PhD, will deliver a corporate presentation at the BIO CEO &
Investor Digital Conference taking place February 16-18, 2021. The presentation will
be available to registered conference attendees for on-demand
viewing beginning February 15, 2021
at 9:00 AM EST via the virtual
conference link. Alternatively, an audio webcast of the
Soligenix corporate presentation is available on the Company's
website via this link.
Key members of Soligenix management will hold one-on-one
meetings throughout the conference. Registered conference
attendees may schedule a meeting with Soligenix via the conference
scheduling link.
"On the heels of our recent SGX301 Commercialization Investor
Webcast Event, the BIO CEO conference comes at an opportune time as
we advance toward new drug application submission to the FDA, while
continuing to highlight SGX301's unique commercial value
proposition for the treatment of cutaneous T-cell lymphoma in the
U.S.," stated Christopher J. Schaber, PhD, President and Chief
Executive Officer of Soligenix. "We remain focused on advancing our
rare disease pipeline and look forward to meeting with high caliber
investment funds and potential pharmaceutical partners during the
conference."
For more information about the BIO CEO & Investor
Conference, please refer to the conference website at
https://www.bio.org/events/bio-ceo-investor-digital-conference.
About Soligenix, Inc.
Soligenix is a late-stage biopharmaceutical company focused on
developing and commercializing products to treat rare diseases
where there is an unmet medical need. Our Specialized
BioTherapeutics business segment is developing and commercializing
SGX301 (synthetic hypericin) as a novel photodynamic therapy
utilizing safe visible light for the treatment of cutaneous T-cell
lymphoma. With a successful Phase 3 study completed, regulatory
approval and commercialization for this product is being advanced
initially in the U.S. Development programs in this business
segment also include our first-in-class innate defense regulator
(IDR) technology, dusquetide (SGX942) for the treatment of
inflammatory diseases, including oral mucositis in head and neck
cancer, and proprietary formulations of oral beclomethasone
17,21-dipropionate (BDP) for the prevention/treatment of
gastrointestinal (GI) disorders characterized by severe
inflammation including pediatric Crohn's disease (SGX203) and acute
radiation enteritis (SGX201).
Our Public Health Solutions business segment includes active
development programs for RiVax®, our ricin toxin vaccine candidate,
SGX943, our therapeutic candidate for antibiotic resistant and
emerging infectious disease, and our research programs to identify
and develop novel vaccine candidates targeting viral infection
including Ebola, Marburg and SARS-CoV-2 (the cause of COVID-19).
The development of our vaccine programs incorporates the use of our
proprietary heat stabilization platform technology, known as
ThermoVax®. To date, this business segment has been supported
with government grant and contract funding from the National
Institute of Allergy and Infectious Diseases (NIAID), the Defense
Threat Reduction Agents (DTRA) and the Biomedical Advanced Research
and Development Authority (BARDA).
For further information regarding Soligenix, Inc., please visit
the Company's website at www.soligenix.com.
This press release may contain forward-looking statements that
reflect Soligenix, Inc.'s current expectations about its future
results, performance, prospects and opportunities, including but
not limited to, potential market sizes, patient populations and
clinical trial enrollment. Statements that are not historical
facts, such as "anticipates," "estimates," "believes," "hopes,"
"intends," "plans," "expects," "goal," "may," "suggest," "will,"
"potential," or similar expressions, are forward-looking
statements. These statements are subject to a number of
risks, uncertainties and other factors that could cause actual
events or results in future periods to differ materially from what
is expressed in, or implied by, these statements, such as
experienced with the COVID-19 outbreak. Soligenix cannot
assure you that it will be able to successfully develop, achieve
regulatory approval for or commercialize products based on its
technologies, particularly in light of the significant uncertainty
inherent in developing therapeutics and vaccines against bioterror
threats, conducting preclinical and clinical trials of therapeutics
and vaccines, obtaining regulatory approvals and manufacturing
therapeutics and vaccines, that product development and
commercialization efforts will not be reduced or discontinued due
to difficulties or delays in clinical trials or due to lack of
progress or positive results from research and development efforts,
that it will be able to successfully obtain any further funding to
support product development and commercialization efforts,
including grants and awards, maintain its existing grants which are
subject to performance requirements, enter into any biodefense
procurement contracts with the U.S. Government or other countries,
that it will be able to compete with larger and better financed
competitors in the biotechnology industry, that changes in health
care practice, third party reimbursement limitations and Federal
and/or state health care reform initiatives will not negatively
affect its business, or that the U.S. Congress may not pass any
legislation that would provide additional funding for the Project
BioShield program. In addition, there can be no assurance as to the
timing or success of any of our clinical/preclinical trials.
Despite the statistically significant result achieved in the SGX301
Phase 3 clinical trial for the treatment of cutaneous T-cell
lymphoma, there can be no assurance that a marketing authorization
from the FDA or EMA will be successful. Further, there can be
no assurance that RiVax® will qualify for a biodefense Priority
Review Voucher (PRV) or that the prior sales of PRVs will be
indicative of any potential sales price for a PRV for
RiVax®. Also, no assurance can be provided that the
Company will receive or continue to receive non-dilutive government
funding from grants and contracts that have been or may be awarded
or for which the Company will apply in the future. These and other
risk factors are described from time to time in filings with the
Securities and Exchange Commission, including, but not limited to,
Soligenix's reports on Forms 10-Q and 10-K. Unless required
by law, Soligenix assumes no obligation to update or revise any
forward-looking statements as a result of new information or future
events.
View original
content:http://www.prnewswire.com/news-releases/soligenix-to-present-at-the-2021-bio-ceo--investor-digital-conference-301226650.html
SOURCE Soligenix, Inc.